All articles tagged with #bowel cancer
A global analysis of 43 studies involving more than 48 million people finds exposure to Helicobacter pylori, a common stomach bacterium, is associated with about a 1.6-fold increase in bowel cancer risk and may account for roughly 22% of colorectal cancer cases worldwide; some evidence suggests eradicating the infection with antibiotics could reduce risk, but results require long-term follow-up and causality remains unproven.
A meta-analysis of 43 studies covering more than 48 million people finds exposure to Helicobacter pylori, a common stomach bacterium, is associated with about 22% of global bowel cancer cases and a 1.6x higher risk, with potential risk reduction if the infection is eradicated—though causality remains unproven and more long-term research is needed.
Kellie Finlayson, a 30-year-old Australian mother, was diagnosed with stage 4 bowel cancer just three months after giving birth to her daughter, after nearly seven years of symptoms she says she dismissed as nothing serious. Initial tests suggested a curable stage 3, but scans soon showed metastasis to the lungs. She endured surgery and more than 80 rounds of chemotherapy, and now lives with metastatic disease while raising awareness on social media about bowel cancer signs and the importance of advocating for oneself in medical care.
Australian mom Kellie Finlayson was diagnosed with stage 4 bowel cancer just three months after giving birth, after years of changes in her bowel habits and fluctuating weight were dismissed. She has since undergone extensive treatment, including surgery and over 80 rounds of chemotherapy, with cancer later spreading to her lungs. Now 30, she continues treatment to keep the disease stable and uses her platform to raise awareness and encourage others to take warning signs seriously.
A 66-year-old woman diagnosed with stage 3 bowel cancer in November 2024 was denied major pelvic surgery at two hospitals due to concerns about the risks and potential impact on her quality of life. With chemotherapy ruled out because of infections, she underwent radiotherapy, but she continues to face hospital visits, a stoma, and urinary drainage alongside recurrent infections and sepsis, prompting her daughter to dispute the decision and argue surgery could improve her mother’s life.
GP Dr Anisha Patel explains that many people dismiss cancer symptoms as stress or ageing, delaying help and risking worse outcomes. The piece highlights five warning signs—unusual fatigue, changes in bowel habits, unexplained weight loss, persistent back pain, and persistent bloating—that should prompt a GP visit if they last or worsen. Delays in diagnosis can increase mortality, while early detection improves survival, so don’t dismiss new or unusual symptoms as simply getting older.
A 45-year-old Melbourne mum of two ignored fatigue, low iron and blood in the stool until a colonoscopy revealed stage-3 bowel cancer, prompting surgery (with a temporary stoma) and six months of chemotherapy. Now in remission and under regular monitoring, she’s speaking out to urge Australians not to dismiss bowel changes as just pregnancy or aging, highlighting rising rates among younger people and backing the Poo Check awareness campaign to normalise conversations about bowel health.
Medical experts warn that colorectal cancer can mimic IBS and remain undiagnosed. Common signs include unexplained weight loss, dark stools or rectal bleeding, new or worsening changes in bowel habits, and sudden overnight GI symptoms. They emphasize timely medical evaluation—especially for those over 45 or with persistent changes—since early detection via colonoscopy can improve outcomes.
Grace Stearn, 54, from Truro, says she had no symptoms when a mailed NHS bowel-screening kit tested positive for stage one bowel cancer, leading to surgery that she calls life-saving. The piece urges others to complete the free test when it arrives and to consult a GP if anything seems off, highlighting the value of early detection and awareness in Cornwall.
In the NEOPRISM-CRC trial, 32 patients with stage II/III MMR-deficient/MSI-high bowel cancer received three doses of pembrolizumab before planned surgery. Seventy percent? No—the article states 59% had no signs of disease after pembrolizumab ahead of surgery, and after nearly three years none of the 32 patients have experienced a recurrence, meaning all remained cancer-free. The results suggest neoadjuvant immunotherapy could change treatment for some bowel cancers and possibly reduce chemotherapy needs, though not all patients benefit. Researchers are exploring blood tests and immune profiling to predict responders, while NHS access to such therapy remains under consideration.
In a 32-patient trial of stage 2–3 bowel cancer with MMR-deficient/MSI-high tumors, a short course of pembrolizumab before surgery kept all patients cancer-free for nearly three years; early data showed 59% had no signs of cancer at surgery, and long-term follow-up found no recurrences, a result that may surpass standard chemotherapy for this subset but is limited by size and specificity. Researchers also used tumor DNA blood tests to monitor response and aim to predict who will benefit. Presented at AACR 2026; longer follow-up is needed.
A health feature outlines five early warning signs of bowel cancer—blood in the stool, persistent changes in bowel habits, abdominal pain, bloating, and unexplained weight loss—and urges anyone experiencing these symptoms to see a GP promptly. The piece highlights the value of early reporting for better outcomes and explains NHS screening options, including at-home FIT tests and follow-up tests like colonoscopy or CT scans if results are positive.
England’s cancer data from 2001–2019 show rising cancer incidence among people under 50, with bowel and ovarian cancers increasing most notably. While obesity and certain behavioral factors contribute, they do not fully explain the trend, suggesting possible age-specific exposures or additional influences (reproductive history, early-life factors, diet, microbiome, and detection changes). The study is observational and cannot prove causation.
A UK-led NEOPRISM-CRC trial treated stage II/III MMR-deficient/MSI-H bowel cancer with up to nine weeks of pembrolizumab before surgery. After ~33 months of follow-up, none of the 32 patients have recurred, and 59% had no detectable cancer at surgery, suggesting preoperative immunotherapy may provide durable control compared with standard surgery followed by chemotherapy. Researchers are also using personalized blood tests and immune profiling to predict responders and monitor remaining disease.
A UK-led NEOPRISM-CRC trial treated 32 patients with stage 2/3 bowel cancer using up to 9 weeks of pembrolizumab before surgery instead of post‑op chemotherapy. About 59% had no detectable cancer after treatment and surgery; after 33 months, none had a cancer relapse. The researchers highlight the potential for durable disease control with preoperative immunotherapy and are developing blood tests and immune profiling to predict responders, noting that roughly 25% relapse is expected with standard treatment after three years.